SEPN: Septerna Corp Price to Sales
Septerna Inc is a biopharmaceutical company developing drugs for GPCR receptors with the backing of strong investors. The current price-to-sales ratio reflects the asset's dynamics, where the parameter value equals 20.60. Effective diversification of raw material suppliers ensures stable pharmacy deliveries and high profitability. The development of the R&D pipeline via the Native Complex platform is accelerating the launch of Phase I clinical trials for oral medications.
Septerna Corp (SEPN) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Septerna Inc|SEPN - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Septerna Pharma|SEPN - Company Aggregate Debts|Debts to Book Value Septerna Corp|SEPN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Septerna|Immediate Liquidity Ratio septerna.com
- net income and valuation ratios data:
SEPN - Net Profit|Projected Future Earnings Septerna Inc|SEPN - Price to Earnings Ratio|Future Price to Earnings Multiple Septerna, Inc.|SEPN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Septerna Corp|SEPN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Septerna|SEPN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months septerna.com|SEPN - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Septerna Inc
- issuer revenue and sales details:
General company analysis:SEPN - septerna.com
The P/S multiple determines the market value of one dollar of revenue, allowing for an assessment of the premium paid for an asset relative to its current sales. For Septerna Inc (SEPN), which focuses on the early stages of GPCR drug development, the ratio of value to sales volume reflects market expectations for future clinical success rather than current operational efficiency.
Competitors of Septerna Inc
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT: P/S Multiple|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Adaptive Biotech - Price-to-Sales Ratio|Market Cap to Revenue CLDX (Celldex)|Market Cap to Sales Volume AUPH|P/S Multiple BCRX (BioCryst)|veratx.com (VERA) - Price to Sales|DNTH - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TRML|PGEN (Precigen, Inc.) - P/S Multiple|P/S Multiple pharming.com|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Price-to-Revenue Coefficient Immunome Bio (IMNM)|GOSS - Price-to-Revenue Ratio|KALV (kalvista.com) - Market Cap to Revenue Ratio|PVLA: P/S Multiple|Market Cap to Revenue Savara Inc|Price-to-Revenue Ratio Rigel Pharmaceuticals Inc|AnaptysBio Inc. (ANAB) - Price-to-Revenue Coefficient|P/S Multiple ATXS|ENGN - Price to Sales|Price-to-Revenue Ratio RAPT Therapeutics RAPT|JBIO (Aerovate Therapeutics, Inc.) - Price-to-Sales Ratio|ACRS - Price-to-Revenue Ratio|KYTX (Kyverna Therapeutics, Inc) - Market Cap to Revenue Ratio|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Price-to-Sales Ratio CABA (cabalettabio.com)|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|THTX: Market Capitalization-to-Revenue Ratio|P/S Multiple AVTX|P/S Multiple Eledon Pharmaceuticals, Inc (ELDN)|Price-to-Revenue Ratio Agenus AGEN|Market Capitalization-to-Revenue Ratio CLYM|ZURA - Price-to-Revenue Ratio|aTyr Pharma Inc (ATYR) - Market Cap to Revenue|ADAG: P/S Multiple|Ikena Oncology (IMA) - P/S Multiple|Market Cap to Revenue STTK|EQ: Market Capitalization-to-Revenue Ratio|P/S Multiple CNTB|Price-to-Revenue Coefficient immunic-therapeutics.com|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc (INMB) - P/S Multiple|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Ratio KZR (Kezar Life Sciences Inc)|P/S Multiple SABS|AKTX - Price to Sales|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GeoVax Labs Inc - P/S Multiple|Price to Sales Edesa Biotech Corp|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Price-to-Sales Ratio CARM (Carisma Therapeutics Inc.)|Market Cap to Revenue XTLB|BOLT (Bolt Bio) - Market Cap to Sales Volume|P/S Multiple HCWB|APVO - Price to Sales|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI - Price-to-Revenue Ratio|XRTX (XORTX Therapeutics Inc) - Market Cap to Revenue Ratio|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|Market Cap to Revenue INDP|SCNI: Market Capitalization-to-Revenue Ratio|P/S Multiple CALI|Price-to-Revenue Coefficient affimed.com|Price-to-Revenue Ratio Allakos ALLK|HOOK: Market Cap to Revenue Ratio|IGM Bio - P/S Multiple|iteostherapeutics.com (ITOS) - Market Cap to Revenue|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TCBP - Price-to-Revenue Coefficient|THRD (Third Harmonic Bio, Inc) - P/S Multiple
